Des tests génétiques et des analyses de protéines peuvent identifier des anomalies de Cdc20.
Protéines Cdc20Analyse génétique
#2
Quels tests sont utilisés pour évaluer Cdc20 ?
Les tests d'immunoblot et de PCR sont couramment utilisés pour évaluer Cdc20.
Protéines Cdc20Immunoblot
#3
Les biopsies peuvent-elles détecter Cdc20 ?
Oui, les biopsies tumorales peuvent révéler des niveaux anormaux de Cdc20.
BiopsieProtéines Cdc20
#4
Y a-t-il des marqueurs associés à Cdc20 ?
Des marqueurs tumoraux peuvent être associés à des niveaux élevés de Cdc20.
Marqueurs tumorauxProtéines Cdc20
#5
Cdc20 est-il lié à des cancers spécifiques ?
Oui, Cdc20 est souvent surexprimé dans divers types de cancers, comme le cancer du sein.
Cancer du seinProtéines Cdc20
Symptômes
5
#1
Quels symptômes sont liés à des anomalies de Cdc20 ?
Les anomalies de Cdc20 peuvent entraîner des symptômes liés à des cancers, comme la fatigue.
FatigueProtéines Cdc20
#2
Les anomalies de Cdc20 provoquent-elles des douleurs ?
Elles peuvent provoquer des douleurs associées aux tumeurs, selon leur localisation.
DouleurProtéines Cdc20
#3
Y a-t-il des symptômes spécifiques au cancer lié à Cdc20 ?
Oui, des symptômes comme des masses palpables ou des saignements peuvent survenir.
Symptômes du cancerProtéines Cdc20
#4
Les anomalies de Cdc20 affectent-elles l'immunité ?
Elles peuvent altérer la réponse immunitaire, augmentant le risque d'infections.
ImmunitéProtéines Cdc20
#5
Cdc20 est-il impliqué dans des syndromes spécifiques ?
Des syndromes de prédisposition au cancer peuvent être liés à des anomalies de Cdc20.
Syndromes de prédispositionProtéines Cdc20
Prévention
5
#1
Peut-on prévenir les anomalies de Cdc20 ?
La prévention passe par un mode de vie sain et le dépistage précoce des cancers.
Prévention du cancerProtéines Cdc20
#2
Y a-t-il des facteurs de risque modifiables pour Cdc20 ?
Oui, éviter le tabac et l'alcool peut réduire le risque de cancers liés à Cdc20.
Facteurs de risqueProtéines Cdc20
#3
Les examens réguliers aident-ils à prévenir les problèmes de Cdc20 ?
Oui, des examens réguliers peuvent aider à détecter précocement les anomalies.
DépistageProtéines Cdc20
#4
L'alimentation influence-t-elle Cdc20 ?
Une alimentation riche en antioxydants peut aider à réduire le risque de cancers.
AlimentationProtéines Cdc20
#5
L'exercice physique a-t-il un impact sur Cdc20 ?
Oui, l'exercice régulier peut diminuer le risque de cancers associés à Cdc20.
Exercice physiqueProtéines Cdc20
Traitements
5
#1
Quels traitements ciblent Cdc20 ?
Des inhibiteurs de Cdc20 sont en développement pour traiter certains cancers.
Inhibiteurs de Cdc20Traitement du cancer
#2
La chimiothérapie affecte-t-elle Cdc20 ?
Oui, certains agents chimiothérapeutiques peuvent influencer l'expression de Cdc20.
ChimiothérapieProtéines Cdc20
#3
Y a-t-il des thérapies géniques pour Cdc20 ?
Des approches de thérapie génique sont explorées pour corriger les anomalies de Cdc20.
Thérapie géniqueProtéines Cdc20
#4
Les traitements ciblés sont-ils efficaces contre Cdc20 ?
Les traitements ciblés montrent des résultats prometteurs dans les cancers liés à Cdc20.
Traitements ciblésProtéines Cdc20
#5
Cdc20 peut-il être une cible pour l'immunothérapie ?
Oui, Cdc20 est une cible potentielle pour des approches d'immunothérapie.
ImmunothérapieProtéines Cdc20
Complications
5
#1
Quelles complications peuvent survenir avec Cdc20 ?
Les complications incluent la progression tumorale et la résistance au traitement.
Complications du cancerProtéines Cdc20
#2
Cdc20 est-il lié à des métastases ?
Oui, une surexpression de Cdc20 est associée à un risque accru de métastases.
MétastasesProtéines Cdc20
#3
Les anomalies de Cdc20 affectent-elles le pronostic ?
Oui, les anomalies de Cdc20 peuvent indiquer un pronostic défavorable dans certains cancers.
PronosticProtéines Cdc20
#4
Cdc20 peut-il entraîner des effets secondaires ?
Les traitements ciblant Cdc20 peuvent provoquer des effets secondaires variés.
Effets secondairesProtéines Cdc20
#5
Y a-t-il des risques de rechute liés à Cdc20 ?
Oui, les cancers avec anomalies de Cdc20 présentent un risque de rechute plus élevé.
RechuteProtéines Cdc20
Facteurs de risque
5
#1
Quels sont les facteurs de risque pour Cdc20 ?
Les antécédents familiaux de cancer et l'exposition à des agents cancérigènes sont des facteurs.
Facteurs de risqueProtéines Cdc20
#2
L'âge influence-t-il le risque lié à Cdc20 ?
Oui, le risque de cancers associés à Cdc20 augmente avec l'âge.
ÂgeProtéines Cdc20
#3
Le sexe joue-t-il un rôle dans les anomalies de Cdc20 ?
Certaines études montrent que le sexe peut influencer le risque de cancers liés à Cdc20.
SexeProtéines Cdc20
#4
Les habitudes alimentaires affectent-elles Cdc20 ?
Oui, une alimentation déséquilibrée peut augmenter le risque de cancers associés à Cdc20.
Habitudes alimentairesProtéines Cdc20
#5
Le stress est-il un facteur de risque pour Cdc20 ?
Le stress chronique peut contribuer à un risque accru de cancers liés à Cdc20.
StressProtéines Cdc20
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Protéines Cdc20 : Questions médicales les plus fréquentes",
"headline": "Protéines Cdc20 : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Protéines Cdc20 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-07-11",
"dateModified": "2025-04-07",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Protéines Cdc20"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Complexe promoteur de l'anaphase",
"url": "https://questionsmedicales.fr/mesh/D064173",
"about": {
"@type": "MedicalCondition",
"name": "Complexe promoteur de l'anaphase",
"code": {
"@type": "MedicalCode",
"code": "D064173",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.167.024"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Protéines Cdc20",
"alternateName": "Cdc20 Proteins",
"code": {
"@type": "MedicalCode",
"code": "D064199",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Yangge Du",
"url": "https://questionsmedicales.fr/author/Yangge%20Du",
"affiliation": {
"@type": "Organization",
"name": "Department of Prosthodontics, Peking University School and Hospital of Stomatology, National Engineering Laboratory for Digital and Material Technology of Stomatology, National Clinical Research Center for Oral Diseases, Beijing Key Laboratory of Digital Stomatology, Beijing, China."
}
},
{
"@type": "Person",
"name": "Ping Zhang",
"url": "https://questionsmedicales.fr/author/Ping%20Zhang",
"affiliation": {
"@type": "Organization",
"name": "Department of Prosthodontics, Peking University School and Hospital of Stomatology, National Engineering Laboratory for Digital and Material Technology of Stomatology, National Clinical Research Center for Oral Diseases, Beijing Key Laboratory of Digital Stomatology, Beijing, China. Electronic address: zhangping332@hsc.pku.edu.cn."
}
},
{
"@type": "Person",
"name": "Yunsong Liu",
"url": "https://questionsmedicales.fr/author/Yunsong%20Liu",
"affiliation": {
"@type": "Organization",
"name": "Department of Prosthodontics, Peking University School and Hospital of Stomatology, National Engineering Laboratory for Digital and Material Technology of Stomatology, National Clinical Research Center for Oral Diseases, Beijing Key Laboratory of Digital Stomatology, Beijing, China. Electronic address: liuyunsong@hsc.pku.edu.cn."
}
},
{
"@type": "Person",
"name": "Shirly Miniowitz-Shemtov",
"url": "https://questionsmedicales.fr/author/Shirly%20Miniowitz-Shemtov",
"affiliation": {
"@type": "Organization",
"name": "Department of Biochemistry, The Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa 31096, Israel."
}
},
{
"@type": "Person",
"name": "Avram Hershko",
"url": "https://questionsmedicales.fr/author/Avram%20Hershko",
"affiliation": {
"@type": "Organization",
"name": "Department of Biochemistry, The Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa 31096, Israel."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Associations between muscle morphology and spasticity in children with spastic cerebral palsy.",
"datePublished": "2023-01-10",
"url": "https://questionsmedicales.fr/article/36706682",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.ejpn.2023.01.007"
}
},
{
"@type": "ScholarlyArticle",
"name": "Efficacy of nabiximols oromucosal spray on spasticity in people with multiple sclerosis: Treatment effects on Spasticity Numeric Rating Scale, muscle spasm count, and spastic muscle tone in two randomized clinical trials.",
"datePublished": "2023-05-01",
"url": "https://questionsmedicales.fr/article/37209500",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.msard.2023.104745"
}
},
{
"@type": "ScholarlyArticle",
"name": "Rebalancing the Spastic Wrist by Transposition of Antagonistic Muscle-Tendon Complex.",
"datePublished": "2022-06-01",
"url": "https://questionsmedicales.fr/article/34711790",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1097/BTH.0000000000000371"
}
},
{
"@type": "ScholarlyArticle",
"name": "Methods of muscle spasticity assessment in children with cerebral palsy: a scoping review.",
"datePublished": "2024-07-11",
"url": "https://questionsmedicales.fr/article/38992701",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s13018-024-04894-7"
}
},
{
"@type": "ScholarlyArticle",
"name": "Focal muscle spasticity has little impact on muscle power for walking in people with Traumatic Brain Injury.",
"datePublished": "2023-05-03",
"url": "https://questionsmedicales.fr/article/37295342",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.clinbiomech.2023.105978"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Acides aminés, peptides et protéines",
"item": "https://questionsmedicales.fr/mesh/D000602"
},
{
"@type": "ListItem",
"position": 3,
"name": "Protéines",
"item": "https://questionsmedicales.fr/mesh/D011506"
},
{
"@type": "ListItem",
"position": 4,
"name": "Protéines du cycle cellulaire",
"item": "https://questionsmedicales.fr/mesh/D018797"
},
{
"@type": "ListItem",
"position": 5,
"name": "Complexe promoteur de l'anaphase",
"item": "https://questionsmedicales.fr/mesh/D064173"
},
{
"@type": "ListItem",
"position": 6,
"name": "Protéines Cdc20",
"item": "https://questionsmedicales.fr/mesh/D064199"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Protéines Cdc20 - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Protéines Cdc20",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-18",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Protéines Cdc20",
"description": "Comment diagnostiquer une anomalie de Cdc20 ?\nQuels tests sont utilisés pour évaluer Cdc20 ?\nLes biopsies peuvent-elles détecter Cdc20 ?\nY a-t-il des marqueurs associés à Cdc20 ?\nCdc20 est-il lié à des cancers spécifiques ?",
"url": "https://questionsmedicales.fr/mesh/D064199?mesh_terms=Muscle+Spasticity#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Protéines Cdc20",
"description": "Quels symptômes sont liés à des anomalies de Cdc20 ?\nLes anomalies de Cdc20 provoquent-elles des douleurs ?\nY a-t-il des symptômes spécifiques au cancer lié à Cdc20 ?\nLes anomalies de Cdc20 affectent-elles l'immunité ?\nCdc20 est-il impliqué dans des syndromes spécifiques ?",
"url": "https://questionsmedicales.fr/mesh/D064199?mesh_terms=Muscle+Spasticity#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Protéines Cdc20",
"description": "Peut-on prévenir les anomalies de Cdc20 ?\nY a-t-il des facteurs de risque modifiables pour Cdc20 ?\nLes examens réguliers aident-ils à prévenir les problèmes de Cdc20 ?\nL'alimentation influence-t-elle Cdc20 ?\nL'exercice physique a-t-il un impact sur Cdc20 ?",
"url": "https://questionsmedicales.fr/mesh/D064199?mesh_terms=Muscle+Spasticity#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Protéines Cdc20",
"description": "Quels traitements ciblent Cdc20 ?\nLa chimiothérapie affecte-t-elle Cdc20 ?\nY a-t-il des thérapies géniques pour Cdc20 ?\nLes traitements ciblés sont-ils efficaces contre Cdc20 ?\nCdc20 peut-il être une cible pour l'immunothérapie ?",
"url": "https://questionsmedicales.fr/mesh/D064199?mesh_terms=Muscle+Spasticity#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Protéines Cdc20",
"description": "Quelles complications peuvent survenir avec Cdc20 ?\nCdc20 est-il lié à des métastases ?\nLes anomalies de Cdc20 affectent-elles le pronostic ?\nCdc20 peut-il entraîner des effets secondaires ?\nY a-t-il des risques de rechute liés à Cdc20 ?",
"url": "https://questionsmedicales.fr/mesh/D064199?mesh_terms=Muscle+Spasticity#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Protéines Cdc20",
"description": "Quels sont les facteurs de risque pour Cdc20 ?\nL'âge influence-t-il le risque lié à Cdc20 ?\nLe sexe joue-t-il un rôle dans les anomalies de Cdc20 ?\nLes habitudes alimentaires affectent-elles Cdc20 ?\nLe stress est-il un facteur de risque pour Cdc20 ?",
"url": "https://questionsmedicales.fr/mesh/D064199?mesh_terms=Muscle+Spasticity#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une anomalie de Cdc20 ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests génétiques et des analyses de protéines peuvent identifier des anomalies de Cdc20."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer Cdc20 ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests d'immunoblot et de PCR sont couramment utilisés pour évaluer Cdc20."
}
},
{
"@type": "Question",
"name": "Les biopsies peuvent-elles détecter Cdc20 ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les biopsies tumorales peuvent révéler des niveaux anormaux de Cdc20."
}
},
{
"@type": "Question",
"name": "Y a-t-il des marqueurs associés à Cdc20 ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des marqueurs tumoraux peuvent être associés à des niveaux élevés de Cdc20."
}
},
{
"@type": "Question",
"name": "Cdc20 est-il lié à des cancers spécifiques ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, Cdc20 est souvent surexprimé dans divers types de cancers, comme le cancer du sein."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont liés à des anomalies de Cdc20 ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les anomalies de Cdc20 peuvent entraîner des symptômes liés à des cancers, comme la fatigue."
}
},
{
"@type": "Question",
"name": "Les anomalies de Cdc20 provoquent-elles des douleurs ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles peuvent provoquer des douleurs associées aux tumeurs, selon leur localisation."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes spécifiques au cancer lié à Cdc20 ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des symptômes comme des masses palpables ou des saignements peuvent survenir."
}
},
{
"@type": "Question",
"name": "Les anomalies de Cdc20 affectent-elles l'immunité ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles peuvent altérer la réponse immunitaire, augmentant le risque d'infections."
}
},
{
"@type": "Question",
"name": "Cdc20 est-il impliqué dans des syndromes spécifiques ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des syndromes de prédisposition au cancer peuvent être liés à des anomalies de Cdc20."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les anomalies de Cdc20 ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention passe par un mode de vie sain et le dépistage précoce des cancers."
}
},
{
"@type": "Question",
"name": "Y a-t-il des facteurs de risque modifiables pour Cdc20 ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, éviter le tabac et l'alcool peut réduire le risque de cancers liés à Cdc20."
}
},
{
"@type": "Question",
"name": "Les examens réguliers aident-ils à prévenir les problèmes de Cdc20 ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des examens réguliers peuvent aider à détecter précocement les anomalies."
}
},
{
"@type": "Question",
"name": "L'alimentation influence-t-elle Cdc20 ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation riche en antioxydants peut aider à réduire le risque de cancers."
}
},
{
"@type": "Question",
"name": "L'exercice physique a-t-il un impact sur Cdc20 ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exercice régulier peut diminuer le risque de cancers associés à Cdc20."
}
},
{
"@type": "Question",
"name": "Quels traitements ciblent Cdc20 ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des inhibiteurs de Cdc20 sont en développement pour traiter certains cancers."
}
},
{
"@type": "Question",
"name": "La chimiothérapie affecte-t-elle Cdc20 ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains agents chimiothérapeutiques peuvent influencer l'expression de Cdc20."
}
},
{
"@type": "Question",
"name": "Y a-t-il des thérapies géniques pour Cdc20 ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des approches de thérapie génique sont explorées pour corriger les anomalies de Cdc20."
}
},
{
"@type": "Question",
"name": "Les traitements ciblés sont-ils efficaces contre Cdc20 ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements ciblés montrent des résultats prometteurs dans les cancers liés à Cdc20."
}
},
{
"@type": "Question",
"name": "Cdc20 peut-il être une cible pour l'immunothérapie ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, Cdc20 est une cible potentielle pour des approches d'immunothérapie."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec Cdc20 ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent la progression tumorale et la résistance au traitement."
}
},
{
"@type": "Question",
"name": "Cdc20 est-il lié à des métastases ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une surexpression de Cdc20 est associée à un risque accru de métastases."
}
},
{
"@type": "Question",
"name": "Les anomalies de Cdc20 affectent-elles le pronostic ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les anomalies de Cdc20 peuvent indiquer un pronostic défavorable dans certains cancers."
}
},
{
"@type": "Question",
"name": "Cdc20 peut-il entraîner des effets secondaires ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements ciblant Cdc20 peuvent provoquer des effets secondaires variés."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques de rechute liés à Cdc20 ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les cancers avec anomalies de Cdc20 présentent un risque de rechute plus élevé."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour Cdc20 ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les antécédents familiaux de cancer et l'exposition à des agents cancérigènes sont des facteurs."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il le risque lié à Cdc20 ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le risque de cancers associés à Cdc20 augmente avec l'âge."
}
},
{
"@type": "Question",
"name": "Le sexe joue-t-il un rôle dans les anomalies de Cdc20 ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines études montrent que le sexe peut influencer le risque de cancers liés à Cdc20."
}
},
{
"@type": "Question",
"name": "Les habitudes alimentaires affectent-elles Cdc20 ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une alimentation déséquilibrée peut augmenter le risque de cancers associés à Cdc20."
}
},
{
"@type": "Question",
"name": "Le stress est-il un facteur de risque pour Cdc20 ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le stress chronique peut contribuer à un risque accru de cancers liés à Cdc20."
}
}
]
}
]
}
Department of Prosthodontics, Peking University School and Hospital of Stomatology, National Engineering Laboratory for Digital and Material Technology of Stomatology, National Clinical Research Center for Oral Diseases, Beijing Key Laboratory of Digital Stomatology, Beijing, China.
Department of Prosthodontics, Peking University School and Hospital of Stomatology, National Engineering Laboratory for Digital and Material Technology of Stomatology, National Clinical Research Center for Oral Diseases, Beijing Key Laboratory of Digital Stomatology, Beijing, China. Electronic address: zhangping332@hsc.pku.edu.cn.
Department of Prosthodontics, Peking University School and Hospital of Stomatology, National Engineering Laboratory for Digital and Material Technology of Stomatology, National Clinical Research Center for Oral Diseases, Beijing Key Laboratory of Digital Stomatology, Beijing, China. Electronic address: liuyunsong@hsc.pku.edu.cn.
Shandong Provincial Key Laboratory of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
Department of Urology, The First Affiliated Hospital of Shandong First Medical University, Jinan, China.
Department of Prosthodontics, Peking University School and Hospital of Stomatology, National Engineering Laboratory for Digital and Material Technology of Stomatology, National Clinical Research Center for Oral Diseases, Beijing Key Laboratory of Digital Stomatology, Beijing, China.
Department of Interventional Radiology, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Section of Cell and Developmental Biology, Division of Biological Sciences, University of California, San Diego, La Jolla, CA, USA. abdesai@ucsd.edu plgonzalez@ucsd.edu.
Department of Cellular and Molecular Medicine, University of California, San Diego, La Jolla, CA, USA.
Ludwig Institute for Cancer Research, San Diego Branch, 9500 Gilman Drive, La Jolla, CA, USA.
Section of Cell and Developmental Biology, Division of Biological Sciences, University of California, San Diego, La Jolla, CA, USA. abdesai@ucsd.edu plgonzalez@ucsd.edu.
Department of Cellular and Molecular Medicine, University of California, San Diego, La Jolla, CA, USA.
Ludwig Institute for Cancer Research, San Diego Branch, 9500 Gilman Drive, La Jolla, CA, USA.
Nanjing Key Laboratory of Pediatrics, Children's Hospital of Nanjing Medical University, Nanjing, China; Jiangsu Key Laboratory of Pediatrics, Nanjing Medical University, Nanjing, China; Department of Nephrology, Children's Hospital of Nanjing Medical University, Nanjing, China.
Due to the heterogeneous clinical presentation of spastic cerebral palsy (SCP), which makes spasticity treatment challenging, more insight into the complex interaction between spasticity and altered m...
We studied associations between spasticity and muscle morphology and compared muscle morphology between commonly observed spasticity patterns (i.e. different muscle activation patterns during passive ...
Spasticity and muscle morphology of the medial gastrocnemius (MG) and semitendinosus (ST) were defined in 74 children with SCP (median age 8 years 2 months, GMFCS I/II/III: 31/25/18, bilateral/unilate...
A moderate negative association (r = -0.624, p < 0.001) was found between spasticity and MG muscle volume, while other significant associations between spasticity and muscle morphology parameters were...
Higher spasticity levels were associated with smaller MG and ST volumes and shorter MG muscles. These muscle morphology alterations were more pronounced in muscles that activated during low-velocity s...
To provide a comprehensive assessment of the treatment effects of nabiximols oromucosal spray on multiple sclerosis spasticity in two clinical trials, GWSP0604 and SAVANT....
Both studies enriched for responders before randomization, defined by a ≥20% improvement in Spasticity 0-10 numeric rating scale (NRS) score. Additionally, SAVANT used randomized re-titration followin...
Mean change from baseline in average daily Spasticity NRS scores was significantly larger for nabiximols than placebo at all postbaseline timepoints, ranging from -0.36 to -0.89 in GWSP0604 and -0.52 ...
Nabiximols leads to improvement in spasticity that was sustained over the 12-week treatment period as measured by average daily Spasticity NRS scores, daily spasm counts, and MAS scores for combinatio...
Upper limb spasticity and spasticity-induced deformities after upper motor neuron lesions because of traumatic brain injury, encephalitis or cerebral palsy inhibit activities of daily living, result i...
Evaluating muscle spasticity in children with cerebral palsy (CP) is essential for determining the most effective treatment strategies. This scoping review assesses the current methods used to evaluat...
A search (to April 2024) used keywords such as muscle spasticity, cerebral palsy, and assessment methods. Selection criteria included articles involving CP children, assessing spasticity objectively/s...
From an initial pool of 1971 articles, 30 met our inclusion criteria. These studies collectively appraised a variety of techniques ranging from well-established clinical scales like the modified Ashwo...
The review discussed the strengths and limitations of each method and concluded that more reliable methods are needed to measure the level of muscle spasticity more accurately....
Spasticity is prevalent following Traumatic Brain Injury. 'Focal' muscle spasticity has been defined as spasticity affecting a localised muscle group, but it's impact on gait kinetics remains unclear....
Ninety-three participants attending physiotherapy for mobility limitations following Traumatic Brain Injury were invited to participate in the study. Participants underwent clinical gait analysis and ...
Hip extensor power generation at initial contact, hip flexor power generation at terminal stance, and knee extensor power absorption at terminal stance were all significantly increased, and ankle powe...
Focal muscle spasticity had little association with abnormal gait kinetics in this cohort of independently ambulant people with Traumatic Brain Injury....
To investigate the influence of muscle position (relaxed vs stretched) on muscle mechanical properties and the ability of myotonometry to detect differences between sides, groups, and sites of testing...
Cross-sectional study....
Outpatient rehabilitation units including private and public centers....
Seventy-one participants (20 subacute stroke, 20 chronic stroke, 31 controls) were recruited (N=71)....
Muscle mechanical properties were measured bilaterally with a MyotonPRO at muscle belly and musculotendinous sites during 2 protocols (muscle relaxed or in maximal bearable stretched position)....
Muscle tone and stiffness of the biceps brachii and gastrocnemius. Poststroke spasticity was evaluated with the Modified Tardieu Scale (MTS). A mixed-model analysis of variance was used to detect diff...
The analysis of variance showed a significant effect of muscle position on muscle mechanical properties (higher tone and stiffness with the muscle assessed in stretched position). Measurements with th...
Myotonometry assessment of mechanical properties with the muscle stretched improves the ability of myotonometry to discriminate between sides in patients after stroke and between people with and witho...
In cerebral palsy (CP), spasticity is the dominant symptom and hip pain is one of the most common secondary conditions. Aetiology is not clear. Musculoskeletal ultrasound (MSUS) is a low-cost, non-inv...
A retrospective case-matched-control study. To investigate associated factors with painful spastic hip and to compare ultrasound findings (focusing on muscle thickness) in children with CP vs. typical...
Paediatric Rehabilitation Hospital in Mexico City, from August to November 2018....
21 children (13 male, 7 + 4.26 years) with CP, in Gross Motor Function Classification System (GMFCS) levels IV to V, with spastic hip diagnosis (cases) and 21 children age- and sex-matched (7 + 4.28 y...
Sociodemographic data, CP topography, degree of spasticity, mobility arch, contractures, Visual Analog Scale (VAS), GMFCS, measurements of the volumes of eight major muscles of the hip joint and MSUS ...
All children with CP group reported chronic hip pain. Associated factors for hip pain (high VAS hip pain score) were degree of hip displacement (percentage of migration), Ashworth Level, GMFCS level V...
Though possibly the most important issue with diminished muscle growth in CP children is the influence on their long-term function, it is likely that training routines that build muscle size may also ...
Botulinum neurotoxin-A (BoNT-A) injections are effective for focal spasticity. However, the impact on muscle strength is not established. This study aimed to investigate the effect of BoNT-A injection...
Although reduced gait asymmetry and trunk control are generally accepted outcomes in stroke patients after having a stroke, the number of studies examining the factors affecting gait symmetry and trun...
What are the effects of gastrocnemius muscle spasticity on trunk control and gait symmetry in chronic stroke patients?...
The sample of the study included 29 individuals aged 40-70 who were diagnosed with stroke at least six months ago. The sociodemographic information of the patients was collected using a descriptive in...
There was a numerical difference between the gait symmetry results of the patients who had a MAS score lower than 2 and those who had a MAS score of 2 or higher, where MAS scores corresponded to gastr...
According to the results of our study, to improve trunk control and gait in stroke survivors, the management of gastrocnemius muscle spasticity should be included in rehabilitation programs. We believ...
Evaluation the effects of dry needling on sonographic, biomechanical and functional parameters of spastic upper extremity muscles....
Twenty-four patients (35-65 years) with spastic hand were randomly allocated into two equal groups: intervention and sham-controlled groups. The treatment protocol was 12-sessions neurorehabilitation ...
The analysis showed that there was a significant reduction in muscle thickness, spasticity and reflex torque and a significant increment in motor function and dexterity in both groups after treatment ...
Dry needling plus neurorehabilitation could decrease muscle thickness, spasticity and reflex torque and improve upper-extremity motor performance and dexterity in chronic stroke patients. These change...
